By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix will use TriLink Biotechnologies' oligonucleotides in several of its kits under an agreement announced today by the firms.

The partners did not disclose terms of the agreement, but said it is a multi-year distribution and supply pact. They also did not specify which Affy kits would contain the oligos.

San Diego-based TriLink makes custom oligos, modified nucleoside triphosphates and CleanAmp PCR products for the diagnostics and OEM markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.